152 related articles for article (PubMed ID: 10800398)
1. h-Caldesmon as a specific marker for smooth muscle tumors. Comparison with other smooth muscle markers in bone tumors.
Watanabe K; Tajino T; Sekiguchi M; Suzuki T
Am J Clin Pathol; 2000 May; 113(5):663-8. PubMed ID: 10800398
[TBL] [Abstract][Full Text] [Related]
2. Is anti-h-caldesmon useful for distinguishing smooth muscle and myofibroblastic tumors? An immunohistochemical study.
Ceballos KM; Nielsen GP; Selig MK; O'Connell JX
Am J Clin Pathol; 2000 Nov; 114(5):746-53. PubMed ID: 11068549
[TBL] [Abstract][Full Text] [Related]
3. [Immunohistochemical differentiation of leiomyocellular tumors and tumors with myogenic differentiation].
Povýsil C; Ciprová V; Dundr P; Horáková M
Cesk Patol; 2003 Apr; 39(2):64-8. PubMed ID: 12874903
[TBL] [Abstract][Full Text] [Related]
4. h-Caldesmon as a specific marker of smooth muscle cell differentiation in some soft tissue tumors of the skin.
D'Addario SF; Morgan M; Talley L; Smoller BR
J Cutan Pathol; 2002 Aug; 29(7):426-9. PubMed ID: 12139638
[TBL] [Abstract][Full Text] [Related]
5. h-Caldesmon in leiomyosarcoma and tumors with smooth muscle cell-like differentiation: its specific expression in the smooth muscle cell tumor.
Watanabe K; Kusakabe T; Hoshi N; Saito A; Suzuki T
Hum Pathol; 1999 Apr; 30(4):392-6. PubMed ID: 10208459
[TBL] [Abstract][Full Text] [Related]
6. Specific but variable expression of h-caldesmon in leiomyosarcomas: an immunohistochemical reassessment of a novel myogenic marker.
Hisaoka M; Wei-Qi S; Jian W; Morio T; Hashimoto H
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):302-8. PubMed ID: 11759055
[TBL] [Abstract][Full Text] [Related]
7. Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma.
Sakamoto A; Oda Y; Yamamoto H; Oshiro Y; Miyajima K; Itakura E; Tamiya S; Honda Y; Ishihara A; Iwamoto Y; Tsuneyoshi M
Virchows Arch; 2002 Apr; 440(4):404-9. PubMed ID: 11956822
[TBL] [Abstract][Full Text] [Related]
8. Expression of smooth muscle markers in so called malignant fibrous histiocytomas.
Hasegawa T; Hasegawa F; Hirose T; Sano T; Matsuno Y
J Clin Pathol; 2003 Sep; 56(9):666-71. PubMed ID: 12944549
[TBL] [Abstract][Full Text] [Related]
9. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].
Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893
[TBL] [Abstract][Full Text] [Related]
10. Pseudosarcomatous myofibroblastic tumor and myosarcoma of the urogenital tract.
Watanabe K; Baba K; Saito A; Hoshi N; Suzuki T
Arch Pathol Lab Med; 2001 Aug; 125(8):1070-3. PubMed ID: 11473460
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue.
Perez-Montiel MD; Plaza JA; Dominguez-Malagon H; Suster S
Am J Dermatopathol; 2006 Apr; 28(2):105-11. PubMed ID: 16625070
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of high molecular weight caldesmon in colorectal pericryptal fibroblasts and tumour stroma.
Nakayama H; Miyazaki E; Enzan H
J Clin Pathol; 1999 Oct; 52(10):785-6. PubMed ID: 10674042
[TBL] [Abstract][Full Text] [Related]
13. Calponin and h-caldesmon in soft tissue tumors: consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates traits of smooth muscle differentiation.
Miettinen MM; Sarlomo-Rikala M; Kovatich AJ; Lasota J
Mod Pathol; 1999 Aug; 12(8):756-62. PubMed ID: 10463476
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of bone GLA protein in primary bone tumors.
Iwasaki R; Yamamuro T; Kotoura Y; Okumura H; Kasai R; Nakashima Y
Cancer; 1992 Aug; 70(3):619-24. PubMed ID: 1320449
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of β-catenin expression in the differential diagnosis of osteosarcoma, osteoblastoma, and chondroblastoma.
Erdogan KE; Pacheco M; Gambarotti M; Magagnoli G; Sbaraglia M; Frisoni T; Righi A; Dei Tos AP
Virchows Arch; 2021 Sep; 479(3):529-535. PubMed ID: 33511430
[TBL] [Abstract][Full Text] [Related]
16. Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone.
Ueda T; Araki N; Mano M; Myoui A; Joyama S; Ishiguro S; Yamamura H; Takahashi K; Kudawara I; Yoshikawa H
J Clin Pathol; 2002 Nov; 55(11):853-8. PubMed ID: 12401825
[TBL] [Abstract][Full Text] [Related]
17. [Pleomorphic and dedifferentiated leiomyosarcoma: a clinicopathologic analysis].
Sun M; Liu JG; Weng QY; Yu L; Wang J
Zhonghua Bing Li Xue Za Zhi; 2018 Feb; 47(2):87-93. PubMed ID: 29429158
[No Abstract] [Full Text] [Related]
18. Potential utility of CD5 immunohistochemical staining in the diagnosis of muscle tumors.
McNab PM; DeMers NM; Schlauder S; Morgan M; Nasir A; Coppola D; Bui MM
Ann Clin Lab Sci; 2009; 39(2):108-13. PubMed ID: 19429795
[TBL] [Abstract][Full Text] [Related]
19. Primary bone tumors. MR morphologic appearance correlated with pathologic examinations.
Golfieri R; Baddeley H; Pringle JS; Leung AW; Greco A; Souhami R; Kemp H
Acta Radiol; 1991 Jul; 32(4):290-8. PubMed ID: 1650569
[TBL] [Abstract][Full Text] [Related]
20. Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors.
Robin YM; Penel N; Pérot G; Neuville A; Vélasco V; Ranchère-Vince D; Terrier P; Coindre JM
Mod Pathol; 2013 Apr; 26(4):502-10. PubMed ID: 23174934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
